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Abstract: This study was designed to investigate the effects of toluene treat-
ment on oxidative stress in rat blood. Since toluene metabolism produces re-
active oxygen and nitrogen species, it was hypothesized that the toluene treat-
ment would: 1) provoke changes in the activities of antioxidant enzymes, 2) 
impair the integrity of the cell membrane and 3) induce structural changes in 
the plasma proteins. Female Wistar rats were treated with toluene intraperito-
nally, at a daily dose of 0.38 mmol/kg body weight for 12 days, and 5 mmol/kg 
body weight for 6 days, respectively, with propylene glycol as the carrier. To-
luene significantly increased superoxide dismutase activity at low doses, cata-
lase activity at high doses and the level of erythrocytes malondialdehyde in 
both treated groups when compared to the control group. The nitrite ( −
2 NO ) le-
vel in both treated groups was not different from that in the control animals. 
Toluene caused oxidative modification of plasma proteins and, consequently, 
changes in the concentration of glycoproteins and lipoproteins when compared to 
the control group. The observed alterations indicate that toluene treatment might 
be involved in free radical processes. 
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INTRODUCTION 
Toluene is an organic solvent widely used in industry. During the process of 
its biotransformation, reactive intermediary products (aryl oxides),1–3 reactive 
oxygen species (ROS), including the superoxide anion ( − •
2 O ), the hydroxyl radi-
cal (OH•) and hydrogen peroxide2 and reactive nitrogen species (RNS), inclu-
ding the nitrosyl radical (NO•),4 could be formed.  − •
2 O  in reaction with NO gene-
rates peroxynitrite (ONOO–), which can cause extensive cell damage through pe-
roxidation of lipids.5 The reactive  − •
2 O  is converted into less toxic H2O2 by su-
peroxide dismutase (SOD). H2O2 may be converted to H2O either by catalase 
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(CAT) or glutathione peroxidase. It may generate the highly reactive free HO• 
via a Fenton reaction, which is believed to be responsible for oxidative damage.6 
HO• leads to peroxidation of polyunsaturated fatty acids (PUFAs), the consti-
tuents of cell and organelle membranes. In the terminal phase of lipid peroxi-
dation (LPO), malondialdehyde (MDA) is produced, as one of the products of de-
gradation of PUFAs.7,8 Exposure of proteins to HO•,  − •
2 O  or both leads to gross 
structural modifications.9 Oxidative damage of plasma proteins commonly occurs 
via reaction with small reactive aldehydes or with aldehydes derived specifically 
from LPO, such as MDA,8 leading to the accumulation of heterogeneous protein 
modifications, classified as advanced glycation end-products (glycoproteins) or 
advanced lipidation end products (lipoproteins).10,11 
Toluene promotes the state of oxidative stress,4 by exhaustion of the anti-oxi-
dative defense enzymes. Hence, it was hypothesized that toluene treatment would: 
1) provoke changes in the activities of the anti-oxidant enzymes, 2) induce the 
process of LPO and 3) lead to oxidative modifications of plasma proteins. 
Previous studies suggest that toluene may be toxic to humans at concentra-
tions lower than the toluene threshold limit value (TLV) (50 ppm) recommended 
by the American Conference of Governmental Industrial Hygienists (ACIGH).12 
It was, therefore, important to investigate the influence of toluene at the concen-
trations lower and higher than the TLV. In this study, the resulting processes in 
the blood of rats exposed to toluene were investigated. 
EXPERIMENTAL 
All the used chemicals were of reagent grade, purchased from Merck (Darmstadt, Ger-
many). 
Animals 
Adult female Wistar rats (180–220 g) were housed in stainless steel grid-bottom cages, 
with free access to food and water. They were maintained under constant conditions (12 h 
light–dark cycles, temperature 22±2 °C). The study was conducted in compliance with the 
EEC Directive 86/609 and was approved by the Ethics Committee of the Faculty of Vete-
rinary Medicine, the University of Belgrade. 
Toluene treatments 
Twelve rats were randomly assigned to each group. The animals were treated daily, at 9 
am, by injection of propylene glycol intraperitonally (i.p.) (vehicle control, group I), or tolu-
ene, at a dose of 0.38 mmol/kg body weight (bw) for 12 days (low dose, group II), a con-
centration lower than the toluene TLV, and at a dose of 5 mmol/kg bw for 6 days (high dose, 
group III), a concentration higher than the toluene TLV. The i.p. route enables the maximal 
absorption of toluene. The rats were killed by diethyl ether inhalation 24 h after the last admi-
nistration. 
Blood (6–8 ml) was obtained from the aorta abdominalis and collected in tubes con-
taining Na citrate (3.8 % w/v) as anticoagulant. The erythrocytes were separated by centrifu-
gation (3000 rpm) and washed three times in saline solution, followed by the immediate asses-
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Erythrocyte enzymes activities 
The CAT activity was determined by the method of Aebi.13 The decrease in H2O2 was 
measured spectrophotometrically at 240 nm (Cecil CE 2021 UV/Vis). One unit of CAT acti-
vity was defined as the activity required to degrade 1.0 μmol H2O2 in 60 s at 25 °C and pH 
7.0. The activity is expressed as 104 μM min-1 (g Hb)-1. 
The SOD activity was determined using a Superoxide Assay Kit (Calbiochem), which 
utilizes 5,6,6a,11b-tetrahydro-3,9,10-trihydroxybenzylo[c]fluorene. This reagent undergoes 
alkaline auto-oxidation, which is accelerated by SOD. The auto-oxidation of this reagent was 
measured at 525 nm (Cecil CE 2021 UV/Vis). The SOD activity is expressed as U (g Hb)-1. 
The SOD isoenzymes (SOD1 and SOD2) were separated on discontinuous polyacryl-
amide gels according to Beauchamp and Fridovich.14 
The LPO in erythrocytes was quantified by measuring the formation of thiobarbituric 
acid reactive substances (TBARS) by the method of Stock and Dormondy,15 and is expressed 
in nmol MDA (g Hb)-1. 
The total Hb content was measured by the cyanmethemoglobin method of Salvati and 
Tentori.16 
The  −
2 NO  levels were analyzed by ELISA assay, using Griess reagent by the method of 
Guevara.17 The absorbance was measured using a microplate reader (Plate reader, Mod. A1, 
Nubenco Enterprises, Inc.) at a wavelength of 545 nm. The results are expressed as μM L-1. 
Native polyacrylamide gel electrophoresis (PAGE) 
Plasma proteins were analyzed by native PAGE (8 %) according to the method of Laem-
mli.18 The native PAGE (8 %) of glycoproteins and lipoproteins were performed according to 
Hames and Rickwood19 and Laemmli18. The glycoproteins and lipoproteins bands were stain-
ed using Pas Schiff’s reagent19,20 and Amido Black,21 respectively. The electrophoretic analy-
ses were performed on a vertical device Mini Ve Hoffer (LKB 2117, Bromma, Uppsala, Sweden). 
The band intensities of the isoenzymes of SOD, plasma proteins, glycoproteins and lipo-
proteins were estimated using Scion Image Beta 4.02 software (http://www.scioncorp.com).22 
The density of each band was estimated with respect to the total area. Data are expressed as 
percentages of the total protein area. 
The plasma protein concentration was determined spectrophotometrically according to 
Lowry.23 
Statistical analyses 
Data are expressed as the means ± standard deviation (SD). Statistical significance was 
tested by the one-way Anova, followed by Dunnett’s t-test. The minimum level of statistical 
significance was set to p<0.05. 
RESULTS 
The changes in the SOD and CAT activities and the MDA levels in the 
erythrocytes are presented in Figs. 1–3, respectively. Toluene treatment at the 
low dose (0.38 mmol/kg bw) significantly increased the total SOD activity (Fig. 
1a), as well as the isoenzyme SOD1 and SOD2 activity, 50.90, 52.21 and 130 %, 
respectively (Fig. 1b and 1c), when compared to the control group. The MDA 
levels also significantly increased 43.69 % upon treatment (p < 0.05). There is a 
tendency towards an increase in the CAT activity. The high dose of toluene (5 
mmol/kg bw) induced the CAT activity (p < 0.001) and MDA levels (p < 0.05) 18 STAJKOVIĆ, BOROZAN and GAĐANSKI-OMEROVIĆ 
by 34.07 and 50.96 %, respectively. No differences in activity of the total SOD, 
SOD1, and SOD2 were observed among treated animals in comparison with the 
control group. 
 
Fig. 1. Activity of SOD: total activity of SOD (a), activity of isoenzyme SOD1 (b), SOD2 (c) 
and activity of SOD on native PAGE (d); I – control group, II – rats treated i.p. with toluene at 
doses of 0.38 mM/kg bw and III – rats treated i.p. with toluene at doses of 5.00 mM/kg bw. 
Fig. 2. CAT activities: I – control group, 
II – rats treated i.p. with toluene at doses 
of 0.38 mM/kg bw and III – rats treated 
i.p. with toluene at doses of 5.00 mM/kg bw.   OXIDATIVE PROCESSES IN RAT BLOOD  19 
Fig. 3. Levels of erythrocytes MDA: I – 
– control group, II – rats treated i.p. with 
toluene at doses of 0.38 mM/kg bw and 
III – rats treated i.p. with toluene at doses 
of 5.00 mM/kg bw. 
The changes in the  −
2 NO  levels and total protein content of the control and 
the exposed groups of rats in blood plasma are presented in Figs. 4 and 5, res-
pectively. Toluene treatment at the low dose decreased the  −
2 NO  levels (p > 0.05) 
and total protein content (p < 0.05) by 8.10 % compared to the non-treated ani-
mals. The high dose of toluene significantly decreased the total protein content  
(p < 0.05) by 9.46 % compared to the control group. The observed decrease in 
the  −
2 NO  levels was not statistically significant. 
Fig. 4. Content of  −
2 NO : I – control group, 
II – rats treated i.p. with toluene at doses 
of 0.38 mM/kg bw and III – rats treated i.p. 
with toluene at doses of 5.00 mM/kg bw. 
The plasma proteins, glycoproteins and lipoproteins were separated by na-
tive PAGE and the results of the quantitative analysis of the gel bands are given 
in Tables Ia, Ib and Ic as percentages of the total area. Seven major protein frac-
tions of plasma proteins are presented in Table Ia. The content of glycoproteins 
and lipoproteins are given in Table Ib and Ic, respectively. 
Toluene treatment induced changes in the concentrations of plasma proteins 
(Table Ia). Toluene treatment at the low dose significantly increased the concen-
tration of alpha-1 glycoprotein (p < 0.001) and decreased the concentration of al-
bumin (p < 0.001) by 37.05 and 12.02 %, respectively, compared to the control 20 STAJKOVIĆ, BOROZAN and GAĐANSKI-OMEROVIĆ 
group. Toluene treatment at the high dose significantly increased the content of 
alpha-1 (p < 0.05), alpha-2 glycoprotein and haptoglobin (p < 0.001) by 23.11, 
67.96 and 101 %, respectively, and decreased albumin (p < 0.001) by 27.27 % 
compared to the values for the control animals. The albumin to globulin ratio 
(A/G) decreased in both groups (≈1.36 fold for the low dose group, and ≈1.91 
fold for the high dose group) compared to the control group. 
Fig. 5. Total content of plasma proteins: 
I – control group, II – rats treated i.p. with 
toluene at doses of 0.38 mM/kg bw and 
III – rats treated i.p. with toluene at doses 
of 5.00 mM/kg bw. 
TABLE Ia. The results of quantitative analysis of gel bands of plasma proteins expressed as 
mean ±SD for: I – control group, II – rats treated i.p. with toluene at doses of 0.38 mM/kg bw, 
and III – rats treated i.p. with toluene at doses of 5.00 mM/kg bw 
Group 
Total area, % (mean±SD) 
A/G 
Albumin Alpha-1 Alpha-2 Transferrin Haptoglobin Gamma  1  Gamma2 
I 
 
II 
 
III 
55.16 
±3.8 
11.12 
±1.26 
5.15 
±1.62 
48.53 
±1.07a 
15.24 
±1.73a 
6.65 
±1.35 
40.19 
±3.72a 
13.69 
±0.66b 
18.65 
±2.36a 
8.16 
±1.49 
9.08 
±0.70 
9.12 
±0.85 
6.37 
±0.79 
6.77 
±1.27 
12.81 
±2.28a 
4.40 
±0.73 
4.81 
±1.47 
4.44 
±1.50 
3.91 
±1.06 
3.43 
±0.83 
3.26 
±0.91 
1.28 
±0.52 
0.94 
±0.15 
0.67 
±0.22 
TABLE Ib. The results of quantitative analysis of gel bands of glycoproteins expressed as 
mean ±SD for: I – control group, II – rats treated i.p. with toluene at doses of 0.38 mM/kg bw, 
and III – rats treated i.p. with toluene at doses of 5.00 mM/kg bw 
Group 
Total area, % (mean±SD) 
IgG 
Albumin  Alpha-1 and 
alpha-2  Transferrin Beta region  Haptoglobin 
I 
II 
III 
17.05±8.40 
11.41±8.72 
5.49±1.59b 
7.79±4.18 
13.81±4.28 
11.16±4.59 
6.53±3.82 
23.03±4.59b
20.73±2.65a
16.62±3.84b 
22.65±4.51a 
24.18±3.33a 
21.28±6.62 
25.58±6.28 
33.13±6.58b 
19.75±1.30 
13.69±3.63b 
6.11±2.70a 
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TABLE Ic. The results of quantitative analysis of gel bands of lipoproteins expressed as mean 
±SD for: I – control group, II – rats treated i.p. with toluene at doses of 0.38 mM/kg bw, and 
III – rats treated i.p. with toluene at doses of 5.00 mM/kg bw 
Group 
Total area, % (mean±SD) 
ApoA-HDL/ApoB-LDL 
Albumin ApoA-HDL  ApoB-LDL 
I 
II 
III 
19.40±1.45 
23.96±3.51 
41.87±5.46 
17.79±2.05 
17.62±5.94 
60.09±6.61a 
26.04±5.79b 
5.43±2.39a 
45.02±4.63b 
1.75±0.64 
3.41±0.90 
8.34±0.52 
ap<0.001; bp<0.05 
Toluene treatment induced changes in the content of glycoproteins (Table 
Ib) and lipoproteins (Table Ic). Statistical analysis of the glycoproteins revealed a 
significantly increased transferrin content (p < 0.05, ≈ 65 %) and the amount of 
proteins of the beta region (p < 0.001, >85 %) and decreased the IgG content in 
both groups compared to the control group (Table Ib). Toluene treatment with 
high dose increased the alpha-1 and alpha-2 glycoproteins and haptoglobin   
(p < 0.05) by 113 and 55.69 %, respectively, and decreased albumin (p < 0.05) by 
67.80 % in comparison to the control group. 
The low dose of toluene given along a period of 12 days significantly in-
creased the level of the apoB-LDL lipoprotein fraction (p < 0.001) by 43.52 % 
and non-significantly decreased the level of the ApoA-HDL lipoprotein fraction 
(p < 0.1), whilst toluene treatment with the high dose significantly increased level 
of ApoB-LDL and albumin (p < 0.05) by 7.52 and 36.00 %, respectively, and de-
creased the level of ApoA-HDL (p < 0.001) by 77.34 %, compared to the control 
group. The ratio ApoA-HDL/ApoB-LDL increased in both groups (≈ two-fold 
for the low dose and ≈ five-fold for the high dose group) compared to the control 
group (Table Ic). 
DISCUSSION 
Toluene is a lipophilic agent and therefore absorbed and retained well by the 
lipid rich areas in organisms.24 Toluene and its metabolites cause a significant 
elevation in the rate of ROS generation.2 The interplay between ROS and anti-
oxidant defense in living aerobic organisms is connected with a series of intra-
cellular antioxidant enzymes, the roles of which are to intercept and inactivate 
reactive radicals. CAT scavenges an excess of free radicals via enzymatic and 
chemical mechanisms, which results in depletion of H2O2. This study showed 
significantly increased CAT activities in rats treated with toluene at the high 
dose. This increase could be attributed to the production of ROS provoked by to-
luene. The ROS scavenging activity of SOD is effective only when it is followed 
by the action of CAT, since the dismutase activity of SOD generates H2O2 from 
− •
2 O .25 The increased concentration of H2O2 and CAT activity in rats treated 
with toluene at the high dose, which appears to inhibit some protective enzymes 
including SOD, allows the production of HO•, formed in Fenton and Haber- 22 STAJKOVIĆ, BOROZAN and GAĐANSKI-OMEROVIĆ 
-Weiss reactions.26 The HO• radicals lead to peroxidation of PUFAs and MDA is 
produced in the terminal phase of LPO. MDA has been mainly employed as a 
marker of oxidative stress in both in vitro and in vivo studies.7,8,27 In the present 
study, toluene significantly increased the erythrocytes MDA levels in both treat-
ed groups. 
Organic solvents (toluene and benzene) and their metabolites induced the 
formation of RNS 28,29 and enhanced the expression of inducible nitric oxide 
synthase (iNOS), which can lead to the formation of excessive NO•.30 The pre-
sent results showed that there were no significant changes in the level of  −
2 NO  in 
plasma of both toluene treated groups. The reason possibly lies in the difference 
in the toluene concentration and, consequently, the difference in NO• release and 
the higher reactivity of NO• with toluene metabolites31 and cellular macromole-
cules. The combination of NO• and  − •
2 O  also results in the rapid generation of the 
highly reactive molecule ONOO−.32 The marker for ONOO− formation is nitra-
tion of tyrosine residues in proteins (Tyr(NO2)). Tyr(NO2) is a post-translational 
modification associated with oxidative stress.29 
Oxidative damage of plasma proteins can be induced directly via H2O2, via 
xenobiotics such as CCl4, through reduced transition metals (Fe2+) and ionizing 
radiation,33 indirectly via reaction with small reactive aldehydes, such as glyoxal, 
methylglyoxal, or with aldehydes derived specifically from LPO, such as MDA,8 
leading to the accumulation of heterogeneous protein modifications, which are 
classified as advanced glycation end products (AGEs)10,11 or advanced lipidation 
end products (ALEs).10,11 The total plasma proteins were analyzed on native PAGE 
to study the changes in individual protein component and changes in the A/G 
ratio. The level of albumin decreased but alpha-1, alpha-2 and haptoglobin in-
creased upon toluene treatment compared to the control group. These proteins are 
classified as acute-phase proteins. Ceron et al.34 showed that concentration of 
acute-phase proteins changes with inflammation, tissue damage, infection, cer-
tain cancers and xenobiotics. Kaukianinen found a positive correlation between 
blood glucose levels and toluene exposure.35 An increased level of glucose leads to 
increased glycosilation of some of the plasma proteins (alpha-1 and alpha-2, trans-
ferrin, proteins of beta region, and haptoglobin),36 as the present results also show. 
The two lipoprotein subfractions responsible for cholesterol transport are 
low density lipoproteins (LDLs) and high density lipoproteins (HDLs).37 Kne-
zević et al.38 showed that human exposure to toluene and xylene increases the 
level of plasma LDL cholesterol but substantially decreases the HDL concen-
tration, thereby increasing the LDL/HDL ratio. The present results are in accor-
dance with these findings. LDL binds receptors via protein ApoB (ApoB-LDL). 
Receptor-bound LDL is internalized by endocytosis into the cell. Oxidative da-
mage of LDL could arise from a number of different causes, including free radi-
cals, such as  − •
2 O  and NO•.39 LDL oxidation is a progressive process leading at   OXIDATIVE PROCESSES IN RAT BLOOD  23 
first to the formation of mildly oxidized LDL, which is defined by a low content 
of lipid-peroxidation derivatives and slight ApoB modifications, and later to ex-
tensively oxidized LDL, which contains high levels of lipid-peroxidation pro-
ducts and severe ApoB alterations.40–42 These severe ApoB alterations lead to 
the failure to bind and internalize LDL, which is probably the reason for the in-
creased LDL levels in the plasma of the animals treated in this study. HDL par-
ticles contain molecules of apolipoprotein A1 (ApoA1-HDL). In addition to its 
role in reverse cholesterol transport (from peripheral tissues to the liver),43,44 
HDL exhibits a protective effect against the cytotoxicity of oxidized LDL, by 
inhibiting LDL oxidation induced by cells and inhibiting the cytotoxicity of 
oxidized LDL.45,46 To the best of our knowledge, the mechanism of
  the 
protective effect of HDL at the cellular level is still
 unclear. This protective effect 
is impaired on account of decreased HDL levels. 
CONCLUSIONS 
The results of this study show that toluene treatment of rats (low and high 
dose) leads to oxidative stress caused by ROS and RNS, and consequently to the: 
1) changed antioxidant enzyme activity, 2) increased LPO and impaired integrity 
of the cell membrane and 3) structural changes in the plasma proteins. Further 
studies are required to evaluate the possible molecular mechanisms of the toxi-
city induced by toluene exposure. 
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ИЗВОД 
УТИЦАЈ ТОЛУЕНА НА ОКСИДАТИВНЕ ПРОЦЕСЕ У КРВИ ПАЦОВА 
СИЛВАНА С.СТАЈКОВИЋ1, СУНЧИЦА З. БОРОЗАН2 И ГОРДАНА ГАЂАНСКИ-ОМЕРОВИЋ3 
1Katedra za higijenu i tehnologiju namirnica animalnog porekla, 2Katedra za hemiju  
3Katedra za biohemiju, Fakultet veterinarske medicine, Univerzitet u Beogradu, 
Bulevar Oslobo|ewa 18, 11000 Beograd 
У овом раду је испитиван утицај толуена на оксидативни стрес у крви пацова. С обзи-
ром на то да метаболизам толуена доводи до стварања реактивних кисеоничних и азотових 
врста, претпостављено је да третирање пацова различитим концентрацијама толуена доводи 
до 1) промене у активности ензима антиоксидативне одбране, 2) нарушавања интегритета 
ћелијске мембране и 3) структурних промена код плазма протеина. Женке пацова соја Wistar 
су подељене у три групе: I група – контролна, II и III група – пацови третирани i.p. толуеном 
свакодневно 12 и 6 дана, дозом од 0,38 mmol/kg телесне масе и 5,0 mmol/kg телесне месе. 
Толуен је статистички значајно повећавао активност SOD у II групи и активност CAT у III 
групи, док је садржај MDA био значајно повећан у обе групе у поређењу са контролном 
групом. Снижење  −
2 NO  у обе третиране групе није било статистички значајно у односу на 
контролну групу. Толуен је довео до оксидативних промена плазма протеина, а самим тим и 
до промене концентрације глико- и липопротеина у односу на контролну групу. Доказане 
промене указују на то да третирање толуеном изазива слободно-радикалске процесе. 
(Примљено 19. фебруара, ревидирано 10. јуна 2008) 24 STAJKOVIĆ, BOROZAN and GAĐANSKI-OMEROVIĆ 
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